Compare Repligen Corporation Common Stock (RGEN) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs TORM plc — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while TORM plc trades at $39.71 (market cap $4.21B). The key difference: Repligen Corporation Common Stock is far larger — about 2.6× TORM plc's market cap, and TORM plc pays a 10.75% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and TORM plc for 23 Days on average.
| RGEN | TRMD | |
|---|---|---|
Market Cap | $11.14B | $4.21B |
Volume | 1,259,263 | 1,504,714 |
Sector | Health | Industrials |
52-Week High | $194.57 | $41.11 |
52-Week Low | $102.87 | $19.39 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.02B | $4.92B |
Dividend Yield | — | 10.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TRMD trades at $41.11, up 0.46% with strong bullish technical signals from moving averages. The company shows robust fundamentals with a P/E of 6.76, net income margin of 35.52%, and ROE of 26.84%. Recent earnings show mixed results with Q2 2026 missing expectations but strong year-over-year growth projected. Analyst consensus is unanimously bullish with 100% buy ratings. The stock faces headwinds from declining spot rates as noted in recent analysis.
Outlook remains positive based on strong profitability and valuation metrics, though near-term pressure from freight rate declines presents risk. The dividend yield of approximately 5.8% provides income support. Institutional accumulation and solid cash flow generation support the bullish case, but investors should monitor tanker rate trends closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
